Posters

Influence of lens status on anatomic and functional outcomes of vitrectomy for rhegmatogenous retinal detachment

Poster Details

First Author: X.Lumi SLOVENIA

Co Author(s):    A. Thaler   T. Kotnik                 

Abstract Details

Purpose:

To determine the influence of lens status on the anatomic and functional results of 23-gauge pars plana vitrectomy (PPV) for primary rhegmatogenous retinal detachment (RRD).

Setting:

Retrospective analysis of consecutive cases with RRD, with or without proliferative vitreoretinopathy, managed by primary PPV at an ophthalmic tertiary referral centre (Eye Hospital, University Medical Centre Ljubljana, Slovenia).

Methods:

128 eyes of 126 patients were included: 65 (50.8%) were phakic, 60 (46.9%) were pseudophakic and 3 (2.3%) were aphakic. Tamponade at the end of PPV was either SF6/C3F8 (n = 96; 75.6%) or silicone oil (SO) (n = 31; 24.4%). The patients completed at least 12 months of follow-up. Success was defined as retinal reattachment 1 year after a single procedure in patients with gas tamponade or 1 year after SO removal in cases with SO tamponade. Statistical comparisons between groups were made using Student's t, Chi-square and Mann–Whitney U test.

Results:

Overall anatomical success rate with retinal reattachment 1 year after a single surgery or SO removal was 91.7%. A redetachment developed in 5 phakic (7.7%) and 6 pseudophakic (10%) eyes (p = 0.71). Mean BCVA at the end of follow-up was logMar 0.42 in phakic vs. logMar 0.22 in pseudophakic eyes (p < 0.001). Mean BCVA at the end of follow-up in patients with gas tamponade was logMar 0.38 in phakic vs. logMar 0.17 in pseudophakic eyes (p < 0.001) and in patients with SO tamponade logMar 0.62 in phakic vs. logMar 0.42 in pseudophakic eyes (p < 0.001).

Conclusions:

High anatomical success rate was achieved in phakic as well as pseudophakic eyes. The redetachment rate was not statistically significant between groups. Better functional results were shown in pseudophakic eyes irrespective of the type of tamponade used.

Financial Disclosure:

NONE